TSHA
TSHA
US8776191061
Taysha Gene Therapies, Inc.
Loading chart...

Valuation & History

Quarterly trend of key valuation metrics

Metric
Current (TTM) TTM Baseline
Q2 '26 30.06.2026
Q1 '26 31.03.2026
Q4 '25 31.12.2025
Market & Enterprise Value
Market Cap
1.46B EUR
2.22B EUR
1.28B EUR
1.57B EUR
Enterprise Value
1.04B EUR
1.82B EUR
1.08B EUR
1.32B EUR
Valuation Multiples
Trailing P/E
--
--
--
--
Forward P/E
-9.71x
--
--
--
Price to Sales
266.73x
403.88x
171.88x
209.85x
Price to Book
3.77x
5.72x
6.06x
6.35x
EV/Revenue
190.47x
331.2x
144.04x
176.44x
EV/EBITDA
-6.87x
--
--
--
Price to FCF (P/FCF)
--
--
--
--
EV/FCF
--
--
--
--
FCF Yield
-5.53%
-6.12%
-8.98%
-4.56%
ende